Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Verici DxLSE:VRCI Days Payable is 309.58 as of Dec. 2025, which is 4% above its 10-year median of 297.26. The stock has 3 warning signs investors should review. Among 190 Medical Diagnostics & Research companies, Verici Dx ranks better than 89.47% on this metric.
Verici Dx's average Accounts Payable for the
six
months ended in Dec. 2025 was £0.60 Mil. Verici Dx's Cost of Goods Sold for the
six
months ended in Dec. 2025 was £0.35 Mil.
Hence, Verici Dx's Days Payable for the
six
months ended in Dec. 2025 was 309.58.
The historical rank and industry rank for Verici Dx's Days Payable or its related term are showing as below:
LSE:VRCI'
s Days Payable Range Over the Past 10 Years
Min: 297.26 Med: 297.26 Max: 341.02
Current: 341.02
During the past 6 years, Verici Dx's highest Days Payable was 341.02. The lowest was 297.26. And the median was 297.26.
LSE:VRCI's Days Payable is ranked better than 89.47% of 190
companies
in the Medical Diagnostics & Research industry
Industry Median: 64.64
vs LSE:VRCI: 341.02
Verici Dx's Days Payable
increased
from Dec. 2024 (0.00) to Dec. 2025 (309.58).
It may suggest that Verici Dxdelayed paying its suppliers.
Verici Dx Days Payable Related Terms
Verici Dx Days Payable Historical Data
* Premium members only.
The historical data trend for Verici Dx's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:VRCI vs TMO, DHR, IDXX: Days Payable Comparison
For the Diagnostics & Research subindustry, Verici Dx's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Verici Dx Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Verici Dx's Days Payable distribution charts can be found below:
* The bar in red indicates where Verici Dx's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Verici Dx's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Verici Dx (LSE:VRCI) has a Days Payable of 309.58 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Verici Dx and its competitors. This is near median its historical median of 297.26. Over the past decade, Verici Dx's Days Payable has ranged from 297.26 to 341.02. According to the industry distribution chart, Verici Dx ranks #20 out of 190 companies in the Medical Diagnostics & Research industry, placing it in the top 10.5%.
Is Verici Dx's Days Payable too high?
Verici Dx's current Days Payable of 309.58 is near median its 10-year median of 297.26. Over the past 10 years, this metric has ranged from a low of 297.26 to a high of 341.02. The Medical Diagnostics & Research industry median Days Payable is 64.64. Verici Dx's value of 309.58 is 378.9% above this industry median. Based on the distribution chart, Verici Dx ranks #20 out of 190 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers.
How does Verici Dx's Days Payable compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Verici Dx ranks #20 out of 190 companies for Days Payable. This places Verici Dx in the top 11% of its industry — outperforming the majority of peers. The industry median Days Payable is 64.64. Verici Dx's value of 309.58 is 378.9% above this benchmark. Historically, Verici Dx's own Days Payable has ranged from 297.26 to 341.02 over the past decade. While the company's 10-year median is 297.26 vs. the industry median of 64.64, Verici Dx has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 64.64, based on 190 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Verici Dx's current Days Payable of 309.58 is 378.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Verici Dx and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 64.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Verici Dx's current Days Payable is 309.58, which is near median its own 10-year median of 297.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Verici Dx stock overvalued right now?
Verici Dx (LSE:VRCI) has a current Days Payable of 309.58. The current Days Payable is 309.58, which is near median its 10-year median of 297.26 and 378.9% above the Medical Diagnostics & Research industry median of 64.64. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Verici Dx (LSE:VRCI), the current Days Payable is 309.58 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Verici Dx PLC is an immuno-diagnostics development company. The company is focused on the development of prognostic and diagnostic tests for kidney transplant patients. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; Tuteva, a post-transplant diagnostic focused upon acute cellular rejection, including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels; and Protega will utilize RNA gene signatures to more accurately risk stratify outcome from fibrosis in a transplant patient. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:VRCI has been successfully added to your 
